Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in Hospitalized COVID-19 Patients
NCT05262309Phase 3Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in COVID-19 pneumonia comparing Pamrevlumab with Standard of care (2 arms). Primary endpoint: Proportion of patients not on ventilatory support at 15 days. Started May 2020; status: completed.
02
Drugs
pamrevlumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05262309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262309.